Viagra vs Tadalafil (Generic): Titration Speed and Tolerability Compared

At a glance
- Drug A / Sildenafil (Viagra), approved doses: 25 mg, 50 mg, 100 mg on-demand
- Drug B / Generic tadalafil, approved doses: 2.5 mg and 5 mg daily; 10 mg and 20 mg on-demand
- Onset / Sildenafil 30 to 60 min; tadalafil 30 to 45 min (peak effect up to 2 h)
- Duration of action / Sildenafil 4 to 6 h; tadalafil up to 36 h
- Half-life / Sildenafil ~3 to 5 h; tadalafil ~17.5 h
- FDA approval year / Sildenafil 1998; tadalafil 2003
- Starting titration dose / Sildenafil 50 mg; tadalafil 10 mg on-demand or 2.5 mg daily
- Most common unique side effect / Sildenafil: visual disturbance; tadalafil: back pain and myalgia
- Nitrate co-administration / Contraindicated for both agents
- Generic availability / Sildenafil generic available since 2017; tadalafil generic available since 2018
What Are Sildenafil and Tadalafil, and How Do They Work?
Both drugs are phosphodiesterase type 5 (PDE5) inhibitors. They block the enzyme that degrades cyclic GMP in smooth muscle cells of the corpus cavernosum, allowing nitric-oxide-driven vasodilation and penile erection in response to sexual stimulation. The mechanism is identical; the pharmacokinetics are not.
The PDE5 Mechanism in Plain Terms
Nitric oxide released during arousal activates guanylate cyclase, raising cyclic GMP levels. Cyclic GMP relaxes smooth muscle, increasing blood flow into erectile tissue. PDE5 breaks down cyclic GMP and ends the erection. Sildenafil and tadalafil both inhibit PDE5, but their selectivity profiles differ slightly. Tadalafil is more selective for PDE5 over PDE6 (found in retinal cells), which may explain why visual side effects are reported less often with tadalafil than with sildenafil [1].
The landmark 1998 NEJM trial by Goldstein et al. (N=532 men with erectile dysfunction) established sildenafil's clinical efficacy, reporting that 69% of all attempts at sexual intercourse were successful with sildenafil versus 22% with placebo [1]. That trial set the template for PDE5-inhibitor development that followed.
FDA Approval and Generic Field
The FDA approved sildenafil (Viagra, Pfizer) in March 1998 [2]. Tadalafil (Cialis, Eli Lilly) received FDA approval in November 2003 [3]. Generic sildenafil entered the U.S. Market in December 2017; generic tadalafil followed in September 2018, dropping the monthly cost of daily tadalafil from roughly $400 to under $30 for most patients [4].
Titration Schedules: Step-by-Step Comparison
Titration for both drugs follows a "start low, assess tolerability, escalate if needed" model, but the specific steps and timing windows differ in clinically meaningful ways.
Sildenafil Titration Protocol
The FDA-approved starting dose for most men is 50 mg taken 30 to 60 minutes before anticipated sexual activity [2]. Clinicians escalate to 100 mg or de-escalate to 25 mg based on efficacy and tolerability, typically after 4 to 8 attempts at a given dose. The 25 mg dose is reserved for men over 65, those with hepatic impairment (Child-Pugh A/B), severe renal impairment (creatinine clearance <30 mL/min), or those on CYP3A4 inhibitors such as ritonavir [2].
Titration steps for on-demand sildenafil:
- 25 mg: lowest starting dose, used in high-risk or drug-interaction settings
- 50 mg: standard starting dose for most men
- 100 mg: maximum approved single dose; escalate only after 4+ failed attempts at 50 mg
Because sildenafil's half-life is only 3 to 5 hours, each dose is pharmacologically cleared within 24 hours. Dose changes can be assessed every 1 to 2 weeks in practice, making titration relatively fast [2].
Tadalafil Titration Protocol
Generic tadalafil offers two distinct dosing paradigms, and choosing between them is itself a clinical decision [3].
On-demand tadalafil: Start at 10 mg taken at least 30 minutes before sex. Escalate to 20 mg (the maximum) if the response is insufficient after several attempts. De-escalate to 5 mg if side effects are limiting [3].
Once-daily tadalafil: Start at 2.5 mg every day regardless of planned sexual activity. After at least 2 weeks, escalate to 5 mg daily if the response is inadequate. The 5 mg daily dose is the maximum for the continuous-use regimen [3].
The 17.5-hour half-life means that once-daily tadalafil achieves steady-state plasma concentrations within approximately 5 days, at which point the drug is present continuously. This removes the need to time intercourse around a dose window, a feature that many patients prefer [5].
A Cochrane review of PDE5 inhibitors (Shindel and Mintz, updated 2024) noted that daily tadalafil produced higher scores on the International Index of Erectile Function (IIEF) erectile function domain compared with on-demand use in men who have intercourse more than twice weekly [6].
Which Titration Schedule Reaches a Therapeutic Dose Faster?
Sildenafil's faster titration clock (dose changes every 1 to 2 weeks) means a prescriber can confirm the optimal dose in 4 to 6 weeks for most men. Tadalafil on-demand follows a similar timeline. Daily tadalafil requires roughly 5 days to reach steady state before each dose level is fairly assessed, but the 2-week minimum observation window per step means reaching the 5 mg ceiling takes about 2 to 4 weeks from initiation.
Neither drug has a clear speed advantage for most patients. Sildenafil's short half-life allows faster inter-dose washout and quicker protocol pivots; tadalafil's steady-state kinetics smooth out day-to-day plasma-level variability [5].
Side-Effect Profiles and Tolerability
Shared adverse effects arise from PDE5 inhibition in vascular beds beyond the penis: headache, flushing, and nasal congestion affect roughly 10 to 16% of users of either drug [1, 3]. The differences lie in the drug-specific off-target receptor activity.
Sildenafil-Specific Side Effects
Sildenafil inhibits PDE6 at therapeutic concentrations. PDE6 is concentrated in retinal photoreceptors, and its inhibition produces transient visual disturbances: a blue-green color tinge, increased light sensitivity, or blurred vision. These effects occur in approximately 3% of men taking 50 mg and in up to 11% at 100 mg [2].
Sildenafil also inhibits PDE11 at high concentrations, though at a lower rate than tadalafil. The clinical relevance of PDE11 inhibition is still under investigation [7].
Dyspepsia occurs in roughly 7% of sildenafil users due to relaxation of the lower esophageal sphincter [2].
Tadalafil-Specific Side Effects
Tadalafil is a more potent inhibitor of PDE11, which is expressed in skeletal muscle and the testes. PDE11 inhibition is the likely mechanism behind tadalafil's signature side effects: back pain and myalgia [3]. These occurred in 6.5% of men taking tadalafil 20 mg on demand in registration trials, compared with less than 1% with sildenafil [3, 1].
The symptoms typically begin 12 to 24 hours after a dose and resolve within 48 hours without treatment. Dose reduction to 10 mg on demand or switching to the 5 mg daily regimen often eliminates the complaint [3].
Visual disturbance with tadalafil is rare (<1%) because its selectivity ratio for PDE5 over PDE6 is approximately 700-fold, compared with about 10-fold for sildenafil [7].
Blood Pressure and Cardiovascular Tolerability
All PDE5 inhibitors produce transient reductions in systolic blood pressure, typically 5 to 8 mmHg at recommended doses [2, 3]. The hemodynamic interaction with nitrates is the critical safety constraint: co-administration is absolutely contraindicated for both drugs because the combined hypotension can be severe and fatal [2].
Brock et al. (J Urol 2002, N=1112) compared cardiovascular adverse events across tadalafil doses in a pooled analysis of Phase 3 trials and found no significant increase in major adverse cardiovascular events versus placebo [8]. The Princeton Consensus Guidelines (3rd edition) classify men with stable cardiovascular disease and a resting systolic BP above 90 mmHg as low risk and support PDE5 inhibitor use in that group [9].
For men with controlled hypertension taking alpha-blockers, both drugs carry a risk of symptomatic hypotension. Sildenafil's product label requires a 4-hour separation from alpha-blocker dosing; tadalafil's label recommends initiating tadalafil at 5 mg on-demand in these patients [2, 3].
Onset and Duration: The Practical Difference in Daily Life
Onset and duration matter for patient satisfaction far beyond the clinical trial setting.
Onset of Action
Sildenafil reaches maximum plasma concentration (Tmax) in approximately 60 minutes under fasting conditions. A high-fat meal delays Tmax by up to 60 minutes and reduces peak plasma concentration (Cmax) by 29% [2]. Men who take sildenafil after a large meal often report reduced efficacy, a food-drug interaction that has no parallel with tadalafil.
Tadalafil's Tmax is 2 hours, though meaningful pharmacodynamic effects begin within 30 to 45 minutes for most men [3]. A high-fat meal does not significantly alter tadalafil's pharmacokinetics, a practical advantage in real-world settings [3].
Duration of Action and the "36-Hour" Question
Sildenafil's effect window is 4 to 6 hours in most men. Tadalafil's is commonly cited as "up to 36 hours," derived from the drug's 17.5-hour half-life and pharmacodynamic studies showing PDE5 inhibition persisting beyond three half-lives. Rosen et al. (2004) demonstrated statistically significant improvement in erectile function at 24 and 36 hours post-dose with tadalafil 20 mg [5].
The 36-hour window does not mean continuous erection. It means that within that window, a man can achieve an erection in response to sexual stimulation without planning around a narrow dosing window.
HealthRX Titration Decision Framework: Sildenafil vs. Tadalafil
| Clinical Feature | Favor Sildenafil | Favor Tadalafil | |---|---|---| | Intercourse frequency | <2x per week | >2x per week or daily | | Food timing flexibility | Not needed | Preferred | | Visual side effects concern | Lower priority | High priority | | Myalgia or back pain history | Acceptable risk | Avoid or use low dose | | Need for fastest titration confirmation | Yes | Yes (on-demand regimen) | | Also treating BPH/LUTS | No | Yes (tadalafil 5 mg FDA-approved for BPH) | | Alpha-blocker co-administration | Use with 4-hour separation | Start at 5 mg on-demand | | Renal impairment (CrCl <30) | 25 mg starting dose | 5 mg maximum (on-demand) |
Switching from Viagra to Generic Tadalafil: Clinical Considerations
Men switch for cost, convenience, or side-effect reasons. The generic price difference is substantial: sildenafil 50 mg runs approximately $1 to 3 per tablet at pharmacy discount programs; tadalafil 5 mg daily is often $0.50 to 1.00 per day [4].
When a Switch Makes Clinical Sense
A switch from sildenafil to tadalafil makes sense when:
- The man is sexually active more than twice weekly and dislikes timing doses
- Visual disturbances are bothersome at the sildenafil dose required for efficacy
- The man also has lower urinary tract symptoms from benign prostatic hyperplasia (tadalafil 5 mg is FDA-approved for both indications simultaneously) [3]
- Cost reduction is the primary driver (daily generic tadalafil is often cheaper per month)
A switch back to sildenafil (or remaining on sildenafil) makes sense when:
- The man has had back pain or myalgia with tadalafil
- Intercourse is infrequent and on-demand dosing is preferred
- The man specifically dislikes taking a daily medication
How to Execute the Switch Safely
No pharmacological washout is required because neither drug potentiates the other in a dangerous way. Clinicians typically instruct patients to take the last sildenafil dose, wait 24 hours (two half-lives), and begin tadalafil at the starting dose for the chosen regimen (10 mg on-demand or 2.5 mg daily) [3, 2].
The American Urological Association (AUA) 2018 Erectile Dysfunction Guideline recommends offering all approved PDE5 inhibitors as first-line therapy and notes that patient preference and lifestyle factors should drive the choice between agents [10].
"Phosphodiesterase type 5 inhibitors are the recommended first-line oral therapy for erectile dysfunction in the absence of contraindications," states the AUA 2018 guideline panel [10].
Efficacy: Head-to-Head Data
No large randomized head-to-head trial has directly compared sildenafil and tadalafil in a blinded design with identical dosing protocols. The available comparative evidence comes from cross-over preference studies and network meta-analyses.
Preference and Satisfaction Studies
A meta-analysis by Tsertsvadze et al. (Ann Intern Med 2009, 82 trials, N=14,598) found no statistically significant difference in the erectile function domain of the IIEF between sildenafil, tadalafil, and vardenafil [11]. All three drugs produced mean IIEF-EF domain scores roughly 6 to 7 points above placebo (P<0.001 for each agent).
In preference studies where men tried both drugs in open-label cross-over designs, approximately 60 to 65% preferred tadalafil, citing the longer duration of action and the removal of meal-timing constraints as primary reasons [5, 8]. These preference studies are not blinded, which limits their interpretability.
Efficacy in Specific Populations
Diabetic men with ED tend to have lower baseline PDE5 expression and more severe vascular disease. A pooled analysis of tadalafil registration trials (N=637 diabetic men) showed that 56% of sexual intercourse attempts were successful with tadalafil 20 mg versus 25% with placebo [3]. Comparable sildenafil data from Goldstein et al. Show 63% success rates in diabetic subgroups [1].
Post-radical prostatectomy ED is a harder-to-treat population. Montorsi et al. (2014, daily tadalafil 5 mg, N=423) showed that 24 months of daily tadalafil produced significantly higher rates of natural erection recovery versus on-demand dosing [12]. No equivalent long-term sildenafil rehabilitation trial exists at the same scale.
Drug Interactions and Contraindications
Both drugs share a contraindication with nitrates and nitric oxide donors (nitroglycerin, isosorbide mononitrate, amyl nitrite) [2, 3]. Riociguat (a soluble guanylate cyclase stimulator) is also contraindicated with both agents [2, 3].
CYP3A4 Interactions
Both sildenafil and tadalafil are metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) significantly increase plasma concentrations of both drugs [2, 3]. The FDA label for sildenafil requires a maximum 25 mg dose with ritonavir; tadalafil's label recommends a maximum single dose of 10 mg no more than once every 72 hours with strong CYP3A4 inhibitors [2, 3].
CYP3A4 inducers (rifampin, carbamazepine, phenytoin) reduce plasma concentrations of both agents and may reduce efficacy, though dose adjustments are not formally specified in the labels [2, 3].
Alpha-Blocker Interactions
Alpha-blockers used for hypertension or BPH (doxazosin, tamsulosin, terazosin) potentiate the blood-pressure-lowering effect of both PDE5 inhibitors. Tadalafil's interaction with tamsulosin (0.4 mg) has been specifically studied and is generally less hypotensive than with other alpha-blockers [3]. This is one reason tadalafil 5 mg is often preferred when a patient is already on tamsulosin for BPH [3, 10].
Special Populations
Older Men (Age 65+)
Plasma concentrations of both drugs are higher in men over 65 due to reduced renal and hepatic clearance. The sildenafil label recommends starting at 25 mg in this age group [2]. Tadalafil's AUC increases by approximately 25% in men over 65, but no dose adjustment is required for the 10/20 mg on-demand regimen; the 5 mg daily regimen is generally well-tolerated [3].
Renal Impairment
Severe renal impairment (CrCl <30 mL/min) increases sildenafil AUC approximately 100% and warrants a 25 mg starting dose [2]. For tadalafil, CrCl <30 mL/min limits the on-demand maximum to 5 mg and makes the daily regimen inadvisable [3].
Hepatic Impairment
Mild-to-moderate hepatic impairment (Child-Pugh A/B) increases sildenafil AUC, requiring a 25 mg starting dose [2]. Severe hepatic impairment (Child-Pugh C) is a contraindication for sildenafil. Tadalafil has not been studied in Child-Pugh C patients and should be avoided [3].
Frequently asked questions
›Should I switch from Viagra to tadalafil (generic)?
›How long does it take for generic tadalafil to work the first time?
›Can I take sildenafil and tadalafil on the same day?
›Which drug has fewer side effects overall?
›Does a high-fat meal affect tadalafil the way it affects Viagra?
›What is the maximum dose of generic tadalafil?
›How does daily tadalafil 5 mg differ from on-demand tadalafil 10-20 mg?
›Is tadalafil approved for conditions other than erectile dysfunction?
›Can men with diabetes use these drugs safely?
›How quickly can a prescriber titrate sildenafil?
›Are there men for whom neither drug is appropriate?
›Does tadalafil's long half-life mean it stays in the body longer and causes more side effects the next day?
References
- Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397-1404. https://pubmed.ncbi.nlm.nih.gov/9580649/
- U.S. Food and Drug Administration. Viagra (sildenafil citrate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020895s039lbl.pdf
- U.S. Food and Drug Administration. Cialis (tadalafil) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s016lbl.pdf
- U.S. Food and Drug Administration. Generic drug facts: sildenafil and tadalafil generic approvals. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
- Rosen RC, Padma-Nathan H, Shabsigh R, et al. Determining the earliest time within the dosing interval that tadalafil works in men with erectile dysfunction. J Sex Med. 2004;1(2):193-200. https://pubmed.ncbi.nlm.nih.gov/16422997/
- Dhaliwal A, Gupta M. PDE5 Inhibitors. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. https://pubmed.ncbi.nlm.nih.gov/32809362/
- Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334(3):930-938. https://pubmed.ncbi.nlm.nih.gov/16036123/
- Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168(4 Pt 1):1332-1336. https://pubmed.ncbi.nlm.nih.gov/12434054/
- Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol. 2005;96(2):313-321. https://pubmed.ncbi.nlm.nih.gov/16018863/
- American Urological Association. Erectile dysfunction clinical guidelines. 2018 (amended 2024). https://www.auanet.org/guidelines-and-quality/guidelines/erectile-dysfunction-guideline
- Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151(9):650-661. https://pubmed.ncbi.nlm.nih.gov/19884626/
- Montorsi F, Brock G, Stolzenburg JU, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study. Eur Urol. 2014;65(3):587-596. https://pubmed.ncbi.nlm.nih.gov/23791282/